GoAI
Get started
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

MLTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$15.76

−$0.11 · -0.69%

Aug 21, 4:00 PM ET

MLTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

31

Expensive

Momentum

80

Gaining

Sentiment

47

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CH
CEO
Jorge Santos da Silva
Listed since
Oct 20, 2020
Employees
130

Market position

Day range

Current $15.76

52-week range

Current $15.76

Open
$15.99
Previous close
$15.87
Volume
1.35M
1.19× average
Average volume
1.13M
Average daily volume
Market cap
1.33B USD
Beta
1.07
Market reference 1
50-day average
$18.6978
-15.71% below average
200-day average
$16.7157
-5.72% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
590.83M USD
P/E (TTM)
-4.09×
P/B (TTM)
2.72×
P/S (TTM)
0×
EV / EBITDA
-2.69×
Earnings yield
-26.75%
Free cash flow yield
-23.07%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-74.66%
Return on assets
-53.56%
Return on invested capital
-64.40%

Financial health

Debt / equity
0.24×
Current ratio
9.27×

Financial statements

Income trends

Operating income

−244.83M USD-71.10%

Net income

−227.32M USD-91.13%
Income trends across reported periods−15.12M USD−98.66M USD−182.19M USD−265.72M USDOperating income, FY2021: −53.58M USDOperating income, FY2022: −65.06M USDOperating income, FY2023: −54.12M USDOperating income, FY2024: −143.09M USDOperating income, FY2025: −244.83M USDNet income, FY2021: −53.64M USDNet income, FY2022: −49.97M USDNet income, FY2023: −36.01M USDNet income, FY2024: −118.94M USDNet income, FY2025: −227.32M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −53.58M USD. Operating income FY2022 −65.06M USD. Operating income FY2023 −54.12M USD. Operating income FY2024 −143.09M USD. Operating income FY2025 −244.83M USD. Net income FY2021 −53.64M USD. Net income FY2022 −49.97M USD. Net income FY2023 −36.01M USD. Net income FY2024 −118.94M USD. Net income FY2025 −227.32M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold2.62M USD———4.97K USD
Gross profit−2.62M USD———−4.97K USD
Research and development202.86M USD112.77M USD31.8M USD42.05M USD35.52M USD
Selling, general, and administrative41.97M USD30.32M USD22.32M USD23.01M USD18.05M USD
Operating expenses242.22M USD143.09M USD54.12M USD65.06M USD53.57M USD
Interest expense7.25M USD————
Depreciation and amortization2.62M USD1.38M USD370.32K USD164.78K USD4.97K USD
Operating income−244.83M USD−143.09M USD−54.12M USD−65.06M USD−53.58M USD
Net income−227.32M USD−118.94M USD−36.01M USD−49.97M USD−53.64M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$42.50

169.67% upside
Past 12 months12-month forecastHigh $50.00Average $42.50Low $35.00

Rating distribution

19 ratings
Strong buy00%
Buy1579%
Hold211%
Sell211%
Strong sell00%

Recent analyst actions

12 institutions
Leerink PartnersmaintainOutperform
Rothschild & CoupgradeNeutralBuy
Clear StreetmaintainBuy

MLTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MLTX

Funds reporting this stock among their holdings, ordered by reported position size.

T. Rowe Price Capital Appreciation Equity ETF logoT. Rowe Price Capital Appreciation Equity ETFTCAF
Market value
3.54M
Weight
0.04%
AUM
8.27B USD
Expense ratio
0.31%
Price / 1D
$42.46+0.35%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
2.42M
Weight
0.01%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
iShares ESG Aware MSCI USA Small-Cap ETF logoiShares ESG Aware MSCI USA Small-Cap ETFESML
Market value
1.29M
Weight
0.04%
AUM
2.92B USD
Expense ratio
0.17%
Price / 1D
$55.83+0.65%
Nuveen ESG Small-Cap ETF logoNuveen ESG Small-Cap ETFNUSC
Market value
537.97K
Weight
0.04%
AUM
1.31B USD
Expense ratio
0.31%
Price / 1D
$51.96+0.60%
Fidelity Nasdaq Composite Index ETF logoFidelity Nasdaq Composite Index ETFONEQ
Market value
490.59K
Weight
—
AUM
10.35B USD
Expense ratio
0.21%
Price / 1D
$103.14+0.41%
Fidelity MSCI Health Care Index ETF logoFidelity MSCI Health Care Index ETFFHLC
Market value
329.84K
Weight
0.01%
AUM
3.29B USD
Expense ratio
0.08%
Price / 1D
$84.66+1.22%
Virtus Biotech Clinical Trials ETF logoVirtus Biotech Clinical Trials ETFBBC
Market value
263.92K
Weight
0.52%
AUM
51.06M USD
Expense ratio
0.65%
Price / 1D
$54.415+1.01%
iShares MSCI World Small-Cap ETF logoiShares MSCI World Small-Cap ETFWSML
Market value
49.28K
Weight
0.01%
AUM
679.74M USD
Expense ratio
0.30%
Price / 1D
$35.8721+0.85%

Continue in GoAI

Research MLTX

research.disclaimer